SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC.
HCC
O-GlcNAcylation
SLC35B4
c-Myc
nucleotide sugar transporters
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
01
2022
accepted:
25
01
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
UDP-GlcNAc is a sugar substrate necessary for the O-GlcNAcylation of proteins. SLC35B4 is one of the nucleotide sugar transporters that transport UDP-GlcNAc and UDP-xylose into the endoplasmic reticulum and Golgi apparatus for glycosylation. The roles of SLC35B4 in hepatocellular carcinoma (HCC) tumorigenesis remain unknown. We find that the expression levels of SLC35B4 are higher in HCC tissues than adjacent non-tumor tissues. SLC35B4 is important for the proliferation and tumorigenesis of HCC cells. Mechanistically, SLC35B4 is important for the O-GlcNAc modification of c-Myc and thus the stabilization of c-Myc, which is required for HCC tumorigenesis. Therefore, SLC35B4 is a promising therapeutic target for treating HCC.
Identifiants
pubmed: 35308201
doi: 10.3389/fphar.2022.851089
pii: 851089
pmc: PMC8924407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
851089Informations de copyright
Copyright © 2022 Jiang, Yang, Yang, Chen, Ji, Xu and Yu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Cancer. 2002 Oct;2(10):764-76
pubmed: 12360279
Nat Commun. 2020 Jan 7;11(1):36
pubmed: 31911580
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
Comput Struct Biotechnol J. 2014 Jun 11;10(16):23-32
pubmed: 25210595
Cancer Res. 2013 Aug 15;73(16):5277-87
pubmed: 23720054
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
J Bioenerg Biomembr. 2018 Jun;50(3):189-198
pubmed: 29344764
Annu Rev Biochem. 2011;80:825-58
pubmed: 21391816
Int J Mol Sci. 2018 Dec 29;20(1):
pubmed: 30597997
World J Gastroenterol. 2014 Dec 21;20(47):18059-60
pubmed: 25548509
Contemp Oncol (Pozn). 2018;22(3):141-150
pubmed: 30455585
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Braz J Med Biol Res. 2006 Sep;39(9):1149-58
pubmed: 16981043
J Biol Chem. 2005 Jul 22;280(29):27230-5
pubmed: 15911612
Mol Cell. 2014 Jun 5;54(5):820-31
pubmed: 24857547
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Crit Rev Oncol Hematol. 2015 Jun;94(3):337-47
pubmed: 25680939
Cell Death Dis. 2019 Jun 7;10(6):452
pubmed: 31175271
Front Endocrinol (Lausanne). 2018 Oct 16;9:599
pubmed: 30464755
Front Endocrinol (Lausanne). 2013 Aug 12;4:99
pubmed: 23964270
PLoS One. 2018 Nov 20;13(11):e0207521
pubmed: 30458018